Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Low-dose Radiation in Recurrent/Metastatic HNSCC
NCT06494995Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Jul 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06494995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494995.